Table 1.

Baseline characteristics of patients

CharacteristicsPatients with AKI (N=224)Patients with No AKI (n=76)P ValueAKI in HospitalP Value
Survivor at 60 d (N=75)aNonsurvivor at 60 d (N=149)b
Age (yr), mean (SD) (IQR)60.1 (11.78) (26–97)52.1 (13.30) (30–89)<0.001c55.9 (11.1) (26–93)62.2 (11.6) (37–97)<0.001c
Female, n (%)84 (38)33 (43)0.3637 (49)47 (32)0.01c
Race, n (%)0.17 (omnibus)0.96 (omnibus)
 White33 (15)7 (9)10 (13)23 (15)
 Black83 (37)23 (30)28 (37)55 (37)
 Hispanic84 (38)32 (42)28 (37)56 (38)
 Other24 (11)14 (18)9 (12)15 (10)
BMI (kg/m2) (n=221), median (IQR)31.12 (28.0–37.11)29 (25.80–33.91)0.02c32.18 (27.1–35.9)30.77 (28.0–38.35)0.48
Diabetes, n (%)107 (48)23 (30)0.008c41 (55)66 (44)0.16
HTN, n (%)154 (69)41 (54)0.02c45 (60)109 (73)0.05c
CAD, n (%)33 (15)7 (9)0.158 (11)25 (17)0.32
COPD, n (%)15 (7)4 (5)0.444 (5)11 (7)0.78
HIV, n (%)5 (2)1 (1)0.263 (4)2 (1)0.34
HFrEF, n (%)12 (5)4 (5)0.583 (4)9 (6)0.76
HFpEF, n (%)6 (3)2 (3)0.670 (0)6 (4)0.18
Cancer, n (%)20 (9)4 (5)0.224 (5)16 (11)0.22
DVT history, n (%)5 (2)2 (3)0.561 (1)4 (3)0.67
Smoker, n (%)57 (25)8 (11)0.006c14 (19)43 (29)0.11
NSAID, n (%)47 (21)17 (22)0.7915 (20)32 (21)0.86
ACE inhibitors, n (%)39 (17)14 (18)0.8410 (13)29 (19)0.35
ARBs, n (%)46 (21)17 (22)0.7313 (17)33 (22)0.48
  • IQR, interquartile range; BMI, body mass index; HTN, hypertension; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; DVT, deep vein thrombosis; NSAIDs, nonsteroidal anti-inflammatory drugs; ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor blockers.

  • a Patients discharged alive or alive in hospital with censorship at end of 60-d follow-up period.

  • b In-hospital death at the end of 60-d follow-up period.

  • c P≤0.05.